The FDA approval for extended room temperature storage conditions for ASCENIV and BIVIGAM is significant for ADMA Biologics. It not only enhances the logistical and storage aspects of these products but also potentially increases their marketability and adoption by reducing storage constraints for distributors and healthcare providers. This could lead to increased sales and market penetration for ADMA's products, positively impacting the company's financial performance and stock price in the short term.